/images/ppid_59c68470-image-176985252764166119.webp)
/images/ppid_a911dc6a-image-176984922777759972.webp)
/images/ppid_a911dc6a-image-176984922254133331.webp)
What is the story about?
Sun Pharmaceutical Industries Ltd
. reported its third quarter earnings on Saturday, January 31, beating Street estimates on all parameters.
Its formulation sales in the US were at $477 million, marginally up by 0.6% from the previous year, the company said. US sales accounted for approximately 27.5% of its total consolidated sales.
The pharma company's net profit of ₹3,368.8 crore was 16% more than last year's ₹2,903 crore. A CNBC-TV18 poll had estimated the net profit to be ₹3,138 crore.
Its revenue increased 13.5% to 15,520.5 crore in the third quarter from ₹13,675.4 crore in the previous year. It was also higher than Street estimates of ₹14,874.7 crore.
Sun Pharma's earnings before interest, tax, depreciation and amortisation (EBITDA) too surpassed Street expectations of ₹4,285 crore to come in at ₹4,984.4 crore, which was up 23.4% from the previous year's ₹4,009 crore.
The company's margin expanded to 31.9% from 29.3% in the year-ago period and from Street expectations of 28.8%.
It reported exceptional items of ₹489.4 crore due to the new labour codes.
Sun Pharma's board also approved an interim dividend of ₹11 per equity share of ₹1 each of the firm for the financial year 2026. The record date for the same is February 5, 2026. The interim dividend will be paid on or before February 16, 2026.
Sun Pharma reported sales of ₹15,469.1 crore in the third quarter, up 15.1% from the previous year.
Its global innovative medicines sales stood at $423 million, including $55 million milestone payment.
The global innovative medicines sales increased 13.2%, accounting for 21.2% of sales, both ex-milestone, the company said.
Sun Pharma shares ended the previous session 0.4% up at ₹1,595 apiece. The stock has declined 7.3% in the past month.
Its formulation sales in the US were at $477 million, marginally up by 0.6% from the previous year, the company said. US sales accounted for approximately 27.5% of its total consolidated sales.
The pharma company's net profit of ₹3,368.8 crore was 16% more than last year's ₹2,903 crore. A CNBC-TV18 poll had estimated the net profit to be ₹3,138 crore.
Its revenue increased 13.5% to 15,520.5 crore in the third quarter from ₹13,675.4 crore in the previous year. It was also higher than Street estimates of ₹14,874.7 crore.
Sun Pharma's earnings before interest, tax, depreciation and amortisation (EBITDA) too surpassed Street expectations of ₹4,285 crore to come in at ₹4,984.4 crore, which was up 23.4% from the previous year's ₹4,009 crore.
The company's margin expanded to 31.9% from 29.3% in the year-ago period and from Street expectations of 28.8%.
It reported exceptional items of ₹489.4 crore due to the new labour codes.
Sun Pharma's board also approved an interim dividend of ₹11 per equity share of ₹1 each of the firm for the financial year 2026. The record date for the same is February 5, 2026. The interim dividend will be paid on or before February 16, 2026.
Sun Pharma reported sales of ₹15,469.1 crore in the third quarter, up 15.1% from the previous year.
Its global innovative medicines sales stood at $423 million, including $55 million milestone payment.
The global innovative medicines sales increased 13.2%, accounting for 21.2% of sales, both ex-milestone, the company said.
Sun Pharma shares ended the previous session 0.4% up at ₹1,595 apiece. The stock has declined 7.3% in the past month.
/images/ppid_59c68470-image-176985005297470183.webp)
/images/ppid_59c68470-image-176985005075174265.webp)
